Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00505934 · ClinicalTrials.gov registry record · Phase 2
Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy
A Phase 2 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT00505934 is a Phase 2 study that has completed, run by UCB Pharma. The registered enrollment target is 19 participants.
The verdict
NCT00505934, a Phase 2 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
Keppra injection is approved in the US as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy. The objective of the current study is to assess the safety, tolerability, and pharmacokinetics, of this formulation in children aged 1 month to 4 years.
Interventions
- DRUG Levetiracetam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2008-05 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00505934
The ClinicalTrials.gov registry entry for NCT00505934 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Levetiracetam is the first listed.
NCT00505934 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00505934 about?
NCT00505934 is a clinical study titled "Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy". Keppra injection is approved in the US as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy. The objective of the current study is to assess the safety, tolerability, and pharmacokinetics, of this formulation in children aged 1 month to 4 years.
What is the current status of trial NCT00505934?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2008-05. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00505934?
The interventions under investigation include: Levetiracetam (DRUG).
Who is sponsoring clinical trial NCT00505934?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.